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ABSTRACT 
Objective: N-benzylidene-5-phenyl-1, 3, 4-thiadiazol-2-amine derivatives: Synthesis and anticancer activity. 
Methods: In the present study five new derivatives of N-benzylidene-5-phenyl-1, 3, 4-thiadiazol-2-amine (Schiff bases containing 1, 3, 4-
thiadiazole) were synthesized according to the literature methods and were characterized by FT-IR, 1
Results: The compounds were found to reduce tumor volume, viable cell count and increase the tumor weight (%) inhibition, ascites cells (%) 
inhibition, non-viable cell count and increase in life span (%ILS). All the compounds exhibited significant (P< 0.01) anticancer activity compared to 
control and the compound 2d & 4d was found to be most potent.  
H NMR spectroscopy and C, H, N analysis. 
Anticancer activity was evaluated in Male Swiss albino mice using Ehrlich’s Ascites carcinoma cells. Compounds were administered at a dose of 25 
mg/kg, body weight intraperitoneally.  
Conclusion: It is concluded that synthesized Schiff bases of 2-amino-5-aryl-1, 3, 4-thiadiazoles derivatives are biologically active and developed into 
useful anticancer agents. 
Keywords: 1, 3, 4-Thiadiazole, Anticancer activity, Tumor cell count, Tumor weight inhibition. 
 
INTRODUCTION 
Cancer continues to be the leading cause of mortality and claims over 
6 million lives each year all over the world [1]. Extensive research has 
been carried out since the past few decades to find relief and cure to 
this silent-killer. Heterocyclic chemistry plays an important role in this 
field of synthesis of anti neoplastic agents. 2, 5-disubstituted-1, 3, 4-
thiadiazole derivatives are important classes of sulfur and nitrogen 
containing organic compounds. The area of the synthesis of 1, 3, 4-
thiadiazole rings continues to grow, and organic chemistry will 
provide more and better methods for the synthesis of this interesting 
heterocyclic compound, allowing the discovery of new drug candidates 
that are more active, more specific and safer. 
They present antimicrobial activity [2, 3], antidepressant [4], 
antituberculosis [5], anti-inflammatory [6], anticonvulsants [7], 
antihypertensive [8], antioxidant [9], antitumor [10] and anticancer 
[10-12] activities. 1, 3, 4-Thiadiazole derivatives have also been 
reported as potent Abl tyrosine kinase inhibitors and cyto-
differentiating agents responsible for their antitumor activity [12]. 1, 
3, 4- Thiadiazoles exhibit wide spectrum of biological activities, 
possibly due to presence of toxophoric >N-C-S- moiety [13]. 
A Schiff base (or azomethine) is a functional group that contains a carbon 
nitrogen double bond with the nitrogen atom connected to an aryl or 
alkyl group but not hydrogen[14]. Schiff bases are usually synthesized 
from the condensation of primary amines and active carbonyl group 
[15]. Schiff  bases are characterized by the −N=CH− (imines) group 
which is important for elucidating the mechanism of transamination and 
racemisation reactions in biological systems and are also known to have 
biological activities such as antimicrobial [16, 17], antifungal [17], 
antitubercular [18] and antitumor [19, 20] activity. Here we can assume 
that compounds containing Schiff bases of 1, 3, 4-thiadiazole 
derivatives may be a potential source for the development of 
anticancer drugs. Considering the potential of this class of 
compounds some new 2, 5, di-substituted 1, 3, 4-thiadiazole 
derivatives were synthesized (1d-5d) as shown in Scheme -1, and 
was studied for their anticancer activity. 
MATERIALS AND METHODS 
Chemistry 
All the melting points were determined by the open capillary 
method and are uncorrected. The purity of compounds was checked 
by TLC on micro plates using Silica-gel-G with detecting agent. IR 
spectra were recorded on Perkin Elmer IR spectrophotometer (KBr 
disc) and 1HNMR spectra on Bruker DRX300 NMR spectrometer 
(DMSO-d6, CDCl3
The title compounds were prepared by following steps 
, and TMS). 
Step 1: Synthesis of thiosemicarbazones (III) 
Aromatic aldehyde I (0.05 mol) dissolved in 60 mL warm alcohol 
and thiosemicarbazide II (0.05 mol) dissolved in 100 mL in warm 
water were mixed slowly with continuous stirring. The product was 
separated immediately on cooling, then filtered with suction, dried 
and recrystallized with 75% ethanol to yield III [21]. 
Step 2: Synthesis of 2-amino-5-aryl-1, 3, 4-thiadiazoles (IV) 
Thiosemicarbazone III (0.015 mol) was suspended in 300 mL warm 
water. To this ferric chloride (0.045 mol) in 100 mL water was 
added quantitatively, slowly with constant stirring. The contents 
were heated at 80–90O
Step 3: Synthesis of Schiff bases of 2-amino-5-aryl-1, 3, 4-
thiadiazole derivatives (V) 
C for 45 minute. The solution was filtered hot, 
and then 100 mL citrate buffer containing citric acid (0.033 mol) and 
sodium citrate (0.015 mol) were added. The resulting mixture was 
neutralized with aq. Ammonia (10%) at pH 7. The required amine 
was separated out, filtered with suction, dried and recrystallized 
with an appropriate solvent to get IV [21, 22]. 
A solution of IV (0.002 mol) was prepared in 20 mL alcohol in a 
round-bottomed flask. Required aldehyde (0.002 mol) dissolved in 
15 mL ethanol was then added to it. The mixture was refluxed for 6 
hours. The volume of alcohol was reduced to half by distillation 
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under reduced pressure in rotary vacuum evaporator. The resulting 
solution was poured on crushed ice. The precipitated compounds V 
was separated by filtration and dried. Finally compounds were 
recrystallized with appropriate solvent [23, 24]. 
General methodology 
 
1d: R1= p-OH, R2= p-Cl, 2d: R1= o-OH, R2= p-N (CH3)2, 3d: R1= p-




1, 3, 4-thiadiazol-2-amine 
Recrystallized with ethanol. Yield: - 76.82%, M. p.- 203-205oC, Molecular 
Weight- 315.78, Molecular Formula- C15 H10 N3 OSCl. FT-IR (KBr, Vmax 
cm-1): 3396, 3242 (O–H and N–H), 3156 (Ar–CH), 833, 725 (Ar-C-Cl), 
1695 (C=N), 660 (C-S), 1599(C=C), 1035, 1166 (N=CH).1H NMR (300 
MHz, DMSO-d6 ppm): δ 9.91 (s, 1H, –N=CH), δ 6.85 (d, 2H, J=9Hz, Ar–H), 
δ 6.95 (d, 2H, J=9Hz, Ar–H), δ 7.68 (d, 2H, J=3Hz, Ar–H), δ 7.65 (d, 2H, 
J=3Hz, Ar–H), δ 7.91 (s, 2H, –OH). Anal. Calcd. ForC15 H10 N3 
Compound-2d: N-(4-dimethylaminobenzylidene)-5-(2-
chlorophenyl) - 1, 3, 4-thiadiazol-2-amine 
OSCl, C, 
57.00, H, 3.16, N, 13.30and found: C, 57.83 H, 3.00, N, 13.10,  
Recrystallized with ethanol. Yield- 81.45%, M. p.- 175-176oC, 
Molecular Weight- 342.85, Molecular Formula- C17H15N4SCl. FT-IR 
(KBr, Vmax cm-1): 3106 (Ar–CH), 721 (Ar-C-Cl), 1637 (C=N), 692 (C-
S), 1582(C=C), 1064, 1132 (N=CH). 1H NMR (300 MHz, DMSO-d6 
ppm): δ 8.81 (s, 1H, –N=CH), δ 3.06 (s, 6H, –N(CH3)2), δ 7.69 (d, 2H, 
J=3Hz, Ar–H), δ 7.59 (d, 2H, J=3Hz, Ar–H), δ 7.88 (s, 1H, Ar–H), δ 7.19 
(s, 1H, Ar–H), δ 7.16 (s, 1H, Ar–H). Anal. Calcd. ForC17H15N4
Compound-3d: N-(2-hydroxybenzylidene)-5-(4-chlorophenyl) - 
1, 3, 4-thiadiazol-2-amine 
SCl. C, 
59.50, H, 4.37 N, 16.33and found: C, 59.46, H, 4.57, N, 16.40 
Recrystallized with ethanol. Yield- 79.95%, M. p.- 218-220oC, Molecular 
Weight- 315.78, Molecular Formula- C15 H10 N3 OSCl. FT-IR (KBr, Vmax 
cm-1): 3273 (O–H and N–H), 3092, 2963 (Ar–CH), 828 (Ar-C-Cl), 1631 
(C=N), 694 (C-S), 1512(C=C), 1090, 1135 (N=CH). 1H NMR (300 MHz, 
DMSO-d6 ppm): δ 9.92 (s, 1H, –N=CH), δ 4.36 (s, 2H, –OH), δ 7.76 (d, 2H, 
J=9Hz, Ar–H), δ 7.63 (d, 2H, J=9Hz, Ar–H), δ 6.79 (s, 1H, Ar–H), δ 7.23 (s, 
1H, Ar–H), δ 7.04 (s, 1H, Ar–H). Anal. Calcd. ForC15 H10 N3
Compound-4d: N-(4-hydroxybenzylidene)-5-(4-chlorophenyl) - 
1, 3, 4-thiadiazol-2-amine 
OSCl. C, 57.00, 
H, 3.16, N, 13.30 and found: C, 57.40, H, 3.28, N, 13.42. 
Recrystallized with ethanol. Yield- 74.14%, m. p.- 210-212oC, 
Molecular Weight- 315.78, Molecular Formula- C15 H10 N3 OSCl. IR 
(KBr, Vmax cm-1): 3274 (OH, NH), 3091 (Ar–CH), 785 (Ar-C-Cl), 1633 
(C=N), 696 (C-S), 1513 (C=C), 1090, 1136 (N=CH). 1H NMR (300 
MHz, DMSO-d6  ppm): 1H NMR (300 MHZ, DMSO d6 p p m): δ 9.76 (s, 
1H, –N=CH), δ 8.86 (s, 2H, –OH), δ 8.03 (d, 2H, Ar–H), δ 7.97 (d, 2H, 
J=9Hz, Ar–H), δ 7.76 (d, 2H, J=9Hz, Ar–H), δ 7.63 (s, 2H, Ar–H). Anal. 
Calcd. For C15 H10 N3
Compound-5d: N-(4-hydroxybenzylidene)-5-(2-chlorophenyl) - 
1, 3, 4-thiadiazol-2-amine 
OSCl. C, 57.00, H, 3.16, N, 13.30 and found: C, 
57.09, H, 3.41, N, 13.36. 
Recrystallized with ethanol. Yield- 71.52%, M. p. - 195-197oC, 
Molecular Weight- 315.78, Molecular Formula- C15 H10 N3 OSCl. IR 
(KBr, Vmax cm-1): 3287 (OH and NH), 755 (Ar-C-Cl), 1637 (C=N), 626 
(C-S), 1509 (C=C), 1064, 1132 (N=CH. 1H NMR (300 MHz, DMSO-d6 
ppm): 1H NMR (300 MHZ, DMSO d6 p p m): δ 8.01 (d, 2H, J = 3 Hz, 
Ar–H), δ 7.99 (d, 2H, J = 3 Hz, Ar–H), δ 7.60 (s, 1H, Ar–H), δ 7.43-7.43 
(m, 1H, Ar-H). Anal. Calcd. For C15 H10 N3
Anticancer evaluation 
OSCl. C, 57.00, H, 3.166, N, 
13.30 and found: C, 57.12, H, 3.01, N, 13.50,  
Experimental animals- Male Swiss albino mice of about 8 weeks old 
with an average body weight of 18-20 g were used for the 
experiment. The animals were acclimatized to the laboratory 
environment and facilitated with 12-hrs light & dark cycles at room 
temperature and they were fed with standard pellet diet and fresh 
water ad libitum for 10 days before commencement of the 
experiment. All procedures described were reviewed and approved 
by the University Animals Ethical Committee. 
Tumor cells- Tumor cells used for anticancer activity were EAC 
(Ehrlich Ascites Carcinoma) cells originated from human breast 
carcinoma by spontaneous passaging. It is an undifferentiated 
tumor, which has lost its epithelial character. On subcutaneous 
inoculation, it grows in the form of solid nodes and upon 
intraperitoneal inoculation ascites rich tumor cells will be produced. 
EAC were maintained in vivo in Swiss Albino mice by passaging 0.1 
mL containing 2x106
Experimental procedure-Male Swiss Albino mice of 8 weeks old with 
an average body weight of 18-20 grams were used. All mice are kept 
on basal metabolic diet with water ad libitum. Male Swiss albino 
mice were divided into 8 groups (n = 12). EAC cells were collected 
from the donor mice and are suspended in sterile isotonic solution 
(0.9% w/v NaCl). The number of tumor cells per mL of this 
suspension was counted under the microscope with the help of 
haemocytometer. All the groups were treated with EAC cells (0.1 mL 
containing 2x10
 cells every 10 days. EAC cells of 9 days old are 
used for the screening of synthesized compounds. 
6
After 24 hrs of tumor inoculation Group III-VII received the 
synthesized compounds 1d-5d at a dose of 25mg/kg, body 
weight/day and Group VIII received the standard drug 5-
Fluorouracil at a dose of 20mg/kg, body weight/day respectively for 
9 consecutive days. Weights of the animals were recorded at 3 days 
interval. Twenty-four hours of last dose and 18 h of fasting, 6 
animals of each group were sacrificed to measure antitumor and 
hematological parameters and the rest were kept with food and 
water ad libitum to check percentage increase in life span of the 
tumor host. The weights of all the animals were recorded before 
they were sacrificed.  
 cells/mice) intraperitoneally except the normal 
group (I). This was taken as day ‘0’. Group-I served as normal saline 
control (5 ml/kg i. p.) and Group-II served as EAC control.  
The animals were anaesthetized and dissected to expose the 
peritoneal cavity and by a syringe, the ascetic fluid was withdrawn 
to a suitable volume, collected in sterile ice-cold saline and 
preserved in ice bath. The total number of living cells/mL in the 
peritoneal fluid of the 6 mice in a group is calculated. The fluid is 
sucked by adsorbent cotton. The weight of 6 mice after sacrifice was 
recorded. After sacrificing the animals, blood was collected to 
evaluate the hematological parameters [23, 25-28]. 
The anti-tumor activity of the compounds were measured in EAC 
animals with respect to the following parameters such as 
i. Tumor weight- The mice were dissected and the ascitic fluid was 
collected from the peritoneal cavity. The tumor weights were 
calculated from the difference in weight of mice before dissection 
and after collection of ascitic fluid after dissection. 
ii. Tumor Volume- The ascitic fluid was collected from the peritoneal 
cavity, and volume was measured by taking it in a graduated 
centrifuge tube. 
iii. Tumor cell count- The ascitic fluid was taken in a WBC pipette and 
diluted 100 times. Then a drop of the diluted cell suspension was 
placed on the Neubauer counting chamber and the numbers of cells 
in the 64 small squares were counted with the help of the 
microscope under 40X magnification. 
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Percentage inhibition of ascitic cells (%TCI) = �1 −
T
C
� x 100 
Where T is the total number of ascitic cells /ml in test animals, C is 
the total number of the ascitic cells /mL in control animals. 
iv. Viable/nonviable tumor cell count-The viability and nonviability of 
the cell were checked by trypan blue assay. The cells were stained 
with trypan blue (0.4% in normal saline) dye. The cells that did not 
take up the dye were viable, and those that took the dye were 
nonviable. These viable and nonviable cells were counted. 
Cell count =
number of cells ×  dilution factor
area x thickness of liquid film
 
v. Effect on Body Weight- The effect of the synthesized test 
compounds and standard drug on body weight of the animals 
were checked by measuring body weight of the mice at 3 days 
interval and percent change of body weight for each group was 
calculated. 
vi. Percentage Increase in Life Span (%ILS)-The effects of synthesized 
test compounds on percentage increases in life span were calculated 
on the basis of mortality of the experimental mice. 
 
%ILS = �
mean survival time of treated group
mean survival time of control group
− 1� x 100 
∵ Mean survival time (MST) =
first death +  last death
2
 
Here, time is denoted by days. 
vii. Hematological Parameters- Blood collected from the animals 
were used for the estimation of hemoglobin (Hb) content, red blood 
cell (RBC) count, and white blood cell (WBC) count by standard 
procedures. 
viii. Statistical analysis- All data are expressed as mean ± SEM. (n = 6 
mice per group). Statistical significance (p) calculated by one-way 
ANOVA between the treated groups and the EAC control followed by 
Dunnett’s Multiple Comparison Test of significance where p < 0.05, p 
< 0.01 and p < 0.001 considered to be significant, highly significant 
and most significant respectively. 
Count of viable cells, non-viable cells and total cells-The ascitic fluid of 
dissected mice of each group was taken in a WBC pipette and diluted 
100 times. Then a drop of the diluted cell suspension was placed on 
the Neubauer counting chamber and the numbers of total EAC cells, 
viable and nonviable cells in the 64 small squares were counted with 
help of microscope. 
Haematological parameters-Before dissection of the animals, blood 
sample were collected through orbital plexus through heparinized 
tubes with the help of thin capillary. Blood sample was taken up to 
0.5 marks of the WBC pipette and RBC pipette and it was diluted up 
to 11 marks (it becomes 20 times dilution) and 101 marks (it 
becomes 200 times dilution) by using WBC and RBC diluting fluid 
respectively.  
Then a drop of this diluted sample was placed in the 
Haemocytometer chamber, and the numbers of cells were counted. 
Sahli’s Hemaoglobinometer is used for determination of hemoglobin 
content. 
DISCUSSION 
1, 3, 4-Thiadiazole and its derivatives are important class of organic 
compounds with diverse activities in various fields such as 
biological, agricultural and industrial. 
The anticancer property of the synthesized compounds was 
evaluated by their ability to inhibit cancer cell growth in ascitic fluid 
of swiss albino mice. Various parameters like percentage inhibition 
of tumor weight (%TWI), percentage inhibition of tumor volume 
(%TVI), percentage inhibition of total cell count (%TCI), viable and 
nonviable cell count, effect on body weight, percentage increase in 
life span (%ILS) and haematological parameters have been taken to 
be considered to establish the potency of the anticancer activity of 
the synthesized compounds. All the compounds have significantly 
reduced the tumor weight and tumor volume when compared to 
EAC control group. Percentage inhibition of tumor weight (%TWI) 
and tumor volume (%TVI) have been observed for test compounds 
were 38.99% to 68.17% and 37.77% to 63.65% respectively. The 
compounds 2d (68.17% and 63.17%) and 4d (67.89% and 63.65%) 
showed the maximum activities for the %TWI and %TVI 
respectively but the values of these compounds are nearly same for 
both the cases (table 1, fig. 1). 
  
Table 1: Tumor weight and tumor volume inhibition of the tested compounds 
Group Compound Dose of drug(mg /kg)   Tumor weight (gram) % TWI Tumor volume (mL) %TVI 
I Normal - - - - - 
II EAC control - 3.18 ± 0.21 0.00 1.26 ± 0.08 0.00 
III EAC + 1d 25 1.13 ± 0.08* 64.49 0.54 ± 0.05* 56.51 
IV EAC + 2d 25 1.01 ± 0.08* 68.17 0.46 ± 0.04* 63.17 
V EAC + 3d 25 1.76 ± 0.19* 44.80 0.78 ± 0.04* 38.25 
VI EAC + 4d 25 1.02 ± 0.09* 67.89 0.45 ± 0.05* 63.65 
VII EAC + 5d 25 1.94 ± 0.25* 38.99 0.78 ± 0.03* 37.77 
VIII EAC + 5-FU 20 0.25± 0.14* 92.15 0.12 ± 0.011* 90.48 
Each value represents the mean ± SEM (n = 6 mice per group), ∗
 
Experimental groups were compared with EAC control group (p < 0.001). 
 
Fig. 1: Percentage inhibition of tumor weight (%TWI), tumor volume (%TVI) and total cells in ascitic fluid (%TCI) compared to the EAC 
control group 
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Percentage inhibitions of total cell count (%TCI) have been observed for 
these compounds are 48.22% to 77.85%, where compound 2d showed 
the maximum activity (77.85%). Compounds 1d, 3d and 4d (75.30%, 
71.78% and 75.17% respectively) also reduce tumor cells significantly 
(table 2, fig. 1). All of these compounds significantly reduced the number 
of viable cells and increase the number of nonviable cell comparing to 
the EAC control group. Compound 1d showed the maximum percentage 
(80.12%) of nonviable cells causing destruction of the EAC cells (table 2). 
 
Table 2: Count of viable, non-viable, Total EAC cells and % inhibition of total cell count 






% of viable 
cells 
) 







I Normal -- -- -- -- -- -- 
II EAC + control 7.37 ± 0.18 0.30 ± 0.02 96.05 3.95 7.67 ± 0.19 0.00 
III EAC + 1d (25mg/kg) 0.69 ±0.15* 1.20 ± 0.19* 36.52 63.48 1.89 ± 0.07* 75.30 
IV EAC + 2d (25mg/kg) 1.36 ±0.22* 0.34 ± 0.03** 80.12 19.88 1.70 ± 0.21* 77.84 
V EAC + 3d (25mg/kg) 1.69 ±0.08* 0.47 ± 0.04 77.97 22.03 2.16 ± 0.11* 71.78 
VI EAC + 4d (25mg/kg) 1.58 ±0.09* 0.32 ± 0.02** 83.31 16.69 1.90 ± 0.09* 75.17 
VII EAC + 5d (25mg/kg) 3.71 ±0.04* 0.26 ± 0.01** 93.25 6.75 3.97 ± 0.22* 48.22 
VIII EAC + 5-Fluorouracil 
(20mg/kg) 
0.06 ±0.01* 0.40 ± 0.023** 12.47 87.53 0.46 ± 0.02* 94.04 
Each value represents the mean ± SEM (n = 6 mice per group). ∗Experimental groups were compared with EAC control group (P < 0.001). 
**Experimental groups were compared with EAC control group (P < 0.05). 
Tumor-bearing mice (EAC control) showed a significant (p < 0.05) 
increase in body weight as compared with group I (normal control). 
Treatment with synthesized compounds (1d-5d, 25 mg/kg, body 
weight) significantly reduced the increase in body weight of EAC 
bearing mice. Whereas at the dose of 25 mg /kg of compounds 1d, 
2d and 4d showed highest retardation of increase in body weight 
(6.87%, 5.93% and 7.09% respectively) nearly as same as normal 
group (5.88%) was statistically significant (p < 0.05) at 9 days after 
tumor implantation when compare with EAC control group 
(12.48%) (table 3, fig. 2). 
 
Table 3: Percentage change of body weight of animals at different intervals was calculated by comparing with the day ‘0’ of the 
experiment 
Group Compound % change of body weight after day 3 % change of body weight after day 6 % change of body weight after day 9 
I normal 2.13 ± 0.64 3.62 ± 0.37** 5.88 ± 0.54*** 
II EAC + control 4.91 ± 0.76 9.25 ± 0.88 12.48 ± 0.81 
III EAC + 1d  
(25mg/kg) 
3.02 ± 0.51* 9.32 ± 0.89 6.87 ± 0.87** 
IV EAC + 2d  
(25mg/kg) 
-6.65 ± 1.92*** 11.13 ± 0.71* 5.93 ± 0.92*** 
V EAC + 3d (25mg/kg) 1.96 ± 1.58 5.92 ± 0.97* 10.23 ± 0.98 
VI EAC + 4d  
(25mg/kg) 
-0.30 ± 0.76** 7.49 ± 1.84 7.09 ± 0.78** 
VII EAC + 5d 
(25mg/kg) 
3.51 ± 0.31* 8.53 ± 0.78* 11.65 ± 0.62* 
VIII EAC + 5-FU (20mg/kg) 1.18 ± 0.71 2.06 ± 0.48*** 2.12 ± 1.51*** 
Each value represents the mean ± SEM (n = 6 mice per group).∗Experimental groups were compared with EAC control group (P < 0.05). **Experimental 
groups were compared with EAC control group (P < 0.01). ***Experimental groups were compared with EAC control group (P < 0.001). 
One of the most reliable criteria for judging the efficiency of any 
anticancer drug is the prolongation of the life span of animals. It may 
be concluded that synthesized drugs act by decreasing the 
nutritional fluid volume and arresting tumor growth increases the 
life span of EAC-bearing mice [29]. All the compounds (1d-5d) 
significantly increase percentage increase in life span (%ILS) 
(94.59%, 110.81%, 48.64%, 137.83% and 70.27% respectively) 
compared to the induced control group. Thus, compounds (1d-5d) 
have notable anti-tumor activity against EAC bearing mice. 
Compound 4d (137.83%) showed maximum %ILS among the test 
compounds whereas standard drug shows 164.86% compared to 
the EAC control group (table 3). 
 
Table 4: Percentage increase in life span (%ILS) 
Group Compound MST (in days) % ILS 
I normal -- -- 
II EAC + control 18.5 0.00 
III EAC + 1d (25mg/kg) 36 94.59 
IV EAC + 2d (25mg/kg) 39 110.81 
V EAC + 3d (25mg/kg) 27.5 48.64 
VI EAC + 4d (25mg/kg) 44 137.83 
VII EAC + 5d (25mg/kg) 31.5 70.27 
VIII EAC + 5-FU (20mg/kg) 49 164.86 
 
Usually, in cancer chemotherapy the major problems that are being 
encountered are of myelosuppression and anemia. The anemia 
encountered in tumor bearing mice is mainly due to reduction in 
RBC or hemoglobin percentage, and this may occur either due to 
iron deficiency or due to hemolytic or myelopathic conditions[29, 
30]. The haematological parameters in the EAC control mice were 
compared with drug treated groups, shown increased in hemoglobin 
content in the drugs treated groups as compared to EAC control 
mice and moderate changes in RBC count were also observed in the 
drug treated mice. The total WBC counts were significantly higher in 
the EAC treated mice when compared with normal mice. Whereas, 
the percentage of WBC count is significantly reduced in synthesized 
drug treated groups of EAC bearing mice as compared to EAC 
control mice (table 5, fig. 3). 
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Fig. 2: Percentage increase in life span (%ILS) compared to EAC control group 
 
Table 5: Haematological parameters- WBC, RBC and Haemoglobin content 
Group Compound WBC count (x109 RBC count (10[12]/L) /L) Haemoglobin (g/dL) 
I normal 5.88 ± 0.35* 9.78 ± 0.35* 14.30 ± 0.52* 
II EAC + control 18.80 ± 0.53 2.79 ± 0.25 8.92 ± 0.28 
III EAC + 1d (25mg/kg) 7.46 ± 0.38 5.16 ± 0.29* 11.95 ± 0.39* 
IV EAC + 2d (25mg/kg) 9.22 ± 0.41* 6.51 ± 0.47* 13.33 ± 0.30* 
V EAC + 3d (25mg/kg) 10.12 ± 0.45* 3.59 ± 0.18 9.08 ± 0.36** 
VI EAC + 4d (25mg/kg) 9.64 ± 0.43* 6.24 ± 0.34* 13.13 ± 0.47* 
VII EAC + 5d (25mg/kg) 12.22 ± 0.41* 4.20 ± 0.24** 9.53 ± 0.38** 
VIII EAC + 5-Fluorouracil (20mg/kg) 6.24 ± 0.36** 7.83 ± 0.39* 13.28 ± 0.52* 
Each value represents the mean ± SEM (n = 6 mice per group). ∗
 
Experimental groups were compared with EAC control group (P < 0.001). 
**Experimental groups were compared with EAC control group (P < 0.05). 
 
Fig. 3: Haematological parameters- WBC (x109
 
/L), RBC (10[12]/L) and Haemoglobin (g/dL) content of different groups 
 
Fig. 4: Tumor cell count. The blue stained cells are non-viable whereas the unstained cells are viable EAC cell. Dye used was trypan blue 
 
CONCLUSION  
All the final synthesized compounds exhibited good anticancer 
activity. Compounds 1d, 2d, 3d and 4d were found to have greater 
anticancer activity. Percentage inhibitions of total cell count (%TCI) 
by these compounds are 75.30%, 77.84%, 71.78% and 75.17% 
respectively, where standard reference drug 5-fluorouracil showed 
94.04%. Compound 5d has moderate (48.22%) anticancer activity.  
The results of the present investigation encourage us to develop 
similar other related compounds and test them for a wide range of 
anticancer activity. Thus from the present study, it can be concluded 
that the synthesized Schiff bases of 2-amino-5-aryl-1, 3, 4-
thiadiazoles derivatives are biologically active and they can 
potentially be developed into useful anticancer agents that can 
prompt future researcher to choose this nucleus to synthesize a 
series of other derivatives containing wide varieties of substituent 
with the aim of obtaining some novel heterocyclic systems with 
enhanced anticancer effectiveness. 
Naskar et al. 
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